Abstract
Recurrent or induction therapy-resistant ANLL carries a grave prognosis. The combination of AMSA at 100 mg/M2 daily for 5 days and etoposide at 200 mg/M2 daily for the first 3 days of therapy was given to 40 patients with refractory ANLL. An additional 17 patients received those two agents plus azacitidine at a dosage of 250 mg/M2 on days 4 and 5. All three drugs were given as one-hour infusions. All patients had normal electrolyte determinations daily and were on cardiac monitors during the period of drug administration. No arrhythmias were detected in 522 doses of AMSA. Toxicities observed were primarily related to myelosuppression. Forty-nine of the 57 patients required hospitalization for suspected or proven infection. Nausea/vomiting and mucositis were the next most commonly occurring toxicities. Responses were seen in 22 patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Weinstein HJ, Mayer RJ, Rosenthal DS, Camitta BM, Coral FS, Nathan DG and Frei E: Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 303:473–478, 1980
Lampkin BC, Woods W, Strauss R, Feig S, Higgins G, Bernstein I, D'Angio G, Chard R, Bleyer A and Hammond D: Current status of the biology and treatment of acute non-lymphocytic leukemia in children. Blood 61:215–228, 1983
O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S and Wittes RE: Etoposide (VP-16–213). N Engl J Med 312:692–700, 1985
Louie AC and Issell BF: Amsacrine (AMSA) — A Clinical Review. J Clin Oncol 3:562–592, 1985
Glover AB, Leyland-Jones BR, Chun HG, Davies B and Hoth DF: Azacitidine: 10 years later. Cancer Treat Rep 71:737–746, 1987
Hakami N, Look AT, Steuber CP, Castleberry R, Harris R, Ravindranath Y and Vietti TJ: Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 5:1022–1025, 1987
Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Gallon DAG, Gralnick HR and Sultan C: Proposals for the classification of the acute leukemias: French-American-British Cooperative Group. Br J Haematol 33:451–458, 1976
Hewlett JS, Battle JD, Bishop RC, Fowler WM, Schwartz SO, Hagen PS and Louis J: Phase II study of A-8103 (NSC-25154) in acute leukemia in adults. Cancer Chemother Rep 42:25–28, 1964
Krischer J, Land VJ, Civin CI, Ragab AH, Mahoney DM and Frankel LS: Evaluation of AMSA in children with acute leukemia. Cancer 54:207–210, 1984
Steuber C, Ruymann F, Culbert S, Krischer J, Civin C, Ragab A, Quddus F, Leventhal B, Ravindranath Y and Wilkinson R: High induction response in childhood acute non-lymphocytic leukemia [ANLL]. Proc Am Soc Clin Oncol 4:163 (#C-631), 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Steuber, C.P., Holbrook, T., Camitta, B. et al. Toxicity trials of amsacrine (AMSA) and etoposide +/− azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study. Invest New Drugs 9, 181–184 (1991). https://doi.org/10.1007/BF00175085
Issue Date:
DOI: https://doi.org/10.1007/BF00175085